Vaccines for Prevention of Hantaviral Fevers

Hantaviruses are highly pathogenic causative agents of hantaviral fevers, including hemorrhagic fever with renal syndrome, registered among people in countries of the Eurasian continent and a disease  called «hantavirus  pulmonary  syndrome»  – in the countries of North and South America. More recently, the spread of hantaviral diseases has been detected in Africa. There are still no drugs for specific antiviral therapy. The most promising method of dealing with hantaviral fevers is specific prophylaxis, that is, vaccination of the population against hantaviruses, which determine the endemicity of different territories. This review summarizes current data on existing and developed vaccines against hantaviral fevers.

1. Oya A. Japanese encephalitis vaccine: the vaccination. International Medical Foundation of Japan 1976; 69–72.

2. Lee H.W., Ahn C.N. Development of a vaccine against hemorrhagic fever with renal syndrome. J. Korean Soc Virol. 1988. 18: 143–148.

3. Lee H.W., Ahn C.N., Song J.W., et al. Field trial of an inactivated vaccine against hemorrhagic fever with renal syndrome in humans. Arch Virol. 1990. 1(Suppl 1): 35–47

4. Yamanishi K, Tanishita O, Tamura M et al. Development of inactivated vaccine against virus causing hemorrhagic fever with renal syndrome. Vaccine. 1988. 6: 278–282.

5. Kim R., Ru Ch., Kim GM et al. Specific prevention of HFRS in the DPRK. Abstracts of the international symposium on HFRS. Leningrad, USSR, 1991:. 16–17. (In Russ.).

6. Kim R, Ryu C, Kim G et al. Antibody formation and epidemiological preventive effect after vaccination with the inactivated vaccine against HFRS. In: Abstract of 2nd symposium on arboviruses in the Mediterranean countries, Dubrovnik, 1989. p. 58.

7. Kim R.J., Ru C, Kim G.M. The special prevention of HFRS in P.D.R of Korea. Chin Clin Exp Virol. 1991. 4: 487–492.

8. Sun Z, Yu Y, Wang W, Wang D. Studies on the purified inactivated epidemic hemorrhagic fever vaccine. Clinical trial of type 1 EHF vaccine in volunteers. In: Abstract of 2nd international conference on HFRS, Beijing, 1992. pp. 109–110.

9. Yu Y.X., Dong G.M., Yao X.J. et al. Comparative studies on the immunogenicity of different types of HFRS inactivated. Virol Sin. 1990. 1: 63–66.

10. Astakhova T., Slonova R., Minskaya L. et al. The elaboration of inactivated vaccine against HFRS. In: Abstract of 3rd international conference on HFRS and hantaviruses, Helsinki, 1995. p. 62.

11. Yu Y.X, Yao X.J, Dong G.M. et al. Antibody response of inactivated HFRS vaccine to homologous and heterologous types of the virus. Chin J Biol. 1990. 3: 14–16.

12. Cho H.W., Howard CR. Antibody response in humans to an inactivated hantavirus vaccine (Hantavax). Vaccine. 1999 17: 2569–2575.

13. Cho H.W., Howard C.R., Lee H.W. Review of an inactivated vaccine against hantaviruses. Intervirology. 2002. 45: 328–333.

14. Sohn Y.M., Rho H.O., Park M.S. et al. Primary humoral immuno responses to formalin inactivated hemorrhagic fever with renal syndrome vaccine (Hantavax): consideration of active immunization in South Korea. Yonsei Med J. 2001. 42: 278–284.

15. Lee H.W., Chu Y.K., Woo Y.D. et al. Vaccine against haemorrhagic fever with renal syndrome. In: Saluzzo JF, Dodet В (eds) Factors in the emergence and control of rodent-borne diseases. Elsevier, Paris, 1999: 267–272.

16. Bozovic B, Lee H.W., Samardzic S. et al. Follow-up of immune response of the vaccines by Hantavax vaccine in endemic foci of hemorrhagic fever with renal syndrome in Yugoslavia. In: Abstract of 5th international conference on HFRS, HPS, and hantaviruses, Veyrier-du-Lac, France, 2001, p 235.

17. de Carvalho N.C, Gonzalez Delia Valle M. et al. A Cross-protection against challenge with Puumala virus after immunization with nucleocapsid proteins from different hantaviruses. Virology. 2002. 76 (13): 6669–6677.

18. Dargeviciute A, Brus S.K., Sasnauskas K. et al. Yeast-expressed Puumala hantavirus nucleocapsid protein induces protection in a bank vole model. Vaccine. 2002. 20 (29–30): 3523–3531.

19. Lee H.W., Chu Y.K., Cui Y.S. et al. Immune reaction of the vaccinated hamster with combination Hantaan-puumala vaccine. J Korean Soc Virol. 1997. 27: 39–47

20. Hwang Y.H., Kang M.S., Lim K.O., Lee S.M. Toxic epidermal necrolysis with ocular involvement following vaccination for hemorrhagic fever with renal syndrome. Yonsei Med. J. 2012. 53 (1): 228–230.

21. Song G, Huang Y et al. Human trial of a bivalent inactivated GHKC vaccine against HFRS. In: Abstract of 2nd international conference on HFRS, Beijing, 1992. p. 103.

22. Dong G., An Q., Zhihue Y., Wenxue L. Efficacy of a chicken embryo tissue culture inactivated HFRS vaccine used in a clinical trial. In: Abstract of 5th international conference on HFRS, HPS and hantaviruses 2001, France, p. 239.

23. Choi Y., Ahn C.J., Seong K.M. et al. Inactivated Hantaan virus vaccine derived from suspension culture of Vero cells. Vaccine. 2003. 21: 1867–1873.

24. Li D, Dong G. Vaccines against hantaviruses in China. In: Abstract of 5th international conference on HFRS, HPS, and hantaviruses, Veyrier-du-Lac, France, 2001. p. 121.

25. Zhao T.G., Ying S et al. Effective appraisement of inactivated vaccine against HFRS prepared from Meriones unguiculatus and Alaetagulus pumillio kerr kidney culture. In: Abstract of 4th international conference on HFRS and hantaviruses, Atlanta, 1998. p. 104.

26. Song G, Huang YC, Hang CS. Preliminary human trial of inactivated golden hamster kidney cell vaccine against HFRS. Vaccine. 1992. 10:.214–216.

27. Liu W.M., Song G, Zhang Q.F. Comparative studies on inactivating methods for production of inactivated cell culture vaccine against epidemic hemorrhagic fever. Chin J Virol. 1992. 3: 141–146.

28. Hang C.S., Xie Y.X., Wang S.W. Advances on development of purified bivalent vaccine against HFRS prepared on Vero cells. In: Abstract of 6th international conference on HFRS, HPS and hantaviruses, Seoul, 2004. p. 152.

29. Tkachenko EA, Dzagurova TK, Nabatnikov PA et al. et al.. Development of an experimental vaccine against hemorrhagic fever with renal syndrome. Medical virology. 2009. 26: 194–196. (In Russ.).

30. Tkachenko EA, Ishmukhametov AA, Dzagurova TK et al. Development of an experimental-industrial technology for the production of a vaccine for the prevention of hemorrhagic fever with renal syndrome. Remedium. 2015. 6: 47–53. (In Russ.).

31. Hao F.Y., Hui L.G., Zhao X.L. Efficacy test for inactivated epidemic hemorrhage fever vaccine using golden hamsters. Chin. J. Biol. 1996. 9: 69–72.

32. Ren K., Lu Q.X., Song G. Serological efficacy of the inactivated golden hamster kidney cell vaccine against hemorrhagic fever with renal syndrome in human trial. Chin J Exp Clin Virol. 1996. 10: 10–15.

33. Zhu Z.Y., Zeng R.F., Yu X.Y. Efficacy of inactivated EHF vaccine in clinical trial. Virol Sin. 1991. 6: 315–319.

34. Yu Y.X., Liu W.X., Nei Z.L. Neutralizing antibody response in humans immunized with Meriones gerbil kidney tissue culture inactivated HFRS vaccine assessed by two methods. Virol. Sin. 1992. 7: 176–180.

35. Chen H.X., Wang N., Zhang Y. Evaluation of the efficacy of vaccines against HFRS and study on their antibody dependent immunization enhancement and immunological strategy. In: Abstract of 4th international conference on HFRS and hantaviruses, Atlanta, 1998. p. 87.

36. Li D. Trends of HFRS epidemiology and the expanded program on immunization with hantavirus vaccines in China. In: Abstract of 8th international conference on HFRS HPS and hantavirus, Athens, 2010. p. 82.

37. Zhang Y.Z, Zou Y., Fu Z.F, Plyusnin A. Hantavirus infections in humans and animals, China. Emerg Infect Dis. 2010. 16 (8):1195–1203.

38. Schmaljohn C.S. Vaccines for hantaviruses: progress and issues. Expert Rev Vaccines. 2012. 11 (5): 511–513.

39. Chu Y.K., Jennings G.B., Schmaljohn C.S. (1995) A vaccinia virus-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses but not Puumala virus. J. Virol. 69 (10): 6417–6423.

40. Schmaljohn C. Vaccines for hantaviruses. Vaccine. 2009. 27: 61–64.

41. Dzagurova TK, Tkachenko EA, Bashkirtsev VN, et al. Isolation and identification of strains of Hantavirus-pathogens of HFRS in the European part of Russia. Medical virology. 2008. 25: 142–150. (In Russ.).

42. Klempa B, Tkachenko EA, Dzagurova TK et al. Hemorrhagic fever with renal syndrome caused by 2 lineages of Dobrava hantavirus, Russia. Emerg Infect Dis. 2008. 14:617–625

43. Dzagurova TK, Morozov VG, Yunicheva YuV et al. The etiological role of the genotypes of the Dobrava virus in the morbidity structure of HFRS. Medical virology. 2009. 26: 165–167. (In Russ.)

44. Dzagurova TK, Solopova ON, Sveshnikov PG, Korotina N.A. et.al. Development of an ELISA test system based on monoclonal antibodies to determine the specific activity of a vaccine against hemorrhagic fever with renal syndrome. Vopr. virusol. 2013. 1: 40–44 (In Russ.)

45. Barkhaleva OA, Vorobyova MS, Ladyzhenskaya IP, Tkachenko EA, Dzagurova TK. Hemorrhagic fever vaccine with renal syndrome. Biological products. 2011. 1: 27–30. (In Russ.).

46. Schmaljohn C., Hasty S., Dalrymple J. Preparation of candidate vaccinia-vectored vaccines for HFRS. Vaccine, 1992; 10: 10–13.

47. Kamrud K., Nelle T., VanderZanden L. et al. Evaluation of naked DNA and alphavirus-based hantavirus vaccines. Abstracts of 4th Intern. Confer. on HFRS and Hantaviruses. Atlanta, USA, 1998, P. 95.

48. 48 Hooper J., Kamrud K., Elgh F. et al. Development and testing of DNA vaccines against hantaviruses. Am. J. of Trop. Med. and Hyg. 1998; 59 (Supplement 3): 124–125.

49. Bharadwaj M., Lyons C., Wortman B., Hjelle B. Genetic immunization with Sin Nombre virus cDNAs induces T cell proliferative responses and antibodies in Balb/C mice. Am J of Trop. Med. and Hyg.. 1998; 59 (Supplement 3), P. 124.

50. Yoshimatsu K., Yoo Y.C., Yoshida R. Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus-expressed proteins. Arch. Virol. 1993; 130 (3–4): 365–376.

51. Schmaljohn C.S., Chu Y.K., Schmaljohn A.L., Dalrymple J.M. Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. Virology. 1990. 64 (7): 3162–3170.

52. McClain D.J., Summers P.L., Harrison S.A. et al. Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J. Med. Virol. 2000; 60: 77–85.

53. Hammerbeck C.D., Wahl-Jensen V, Hooper J.W. Hantavirus. In: Barrett ADT, Stanberry L.R. (eds) Vaccines for biodefense and emerging and neglected diseases. Academic Press/Elsevier, London, 2009: 379–412.

54. Safronetz D, Hegde N.R., Ebihara H. et al. Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with Andes virus. J Virol. 2009. 83: 7285–7295.

55. Yuan Z.G., Li X.M., Mahmmod Y.S., Wang X.H. A single immunization with a recombinant canine adenovirus type 2 expressing the seoul virus Gn glycoprotein confers protective immunity against seoul virus in mice. Vaccine. 2009; 27: 5247–5251.

56. Yuan Z.G., Luo S.J., Xu H.J. Generation of E3-deleted canine adenovirus type 2 expressing the Gc glycoprotein of Seoul virus by gene insertion or deletion of related terminal region sequences. J. Gen. Virol. 2010; 91: 1764–1771

57. Giese M. DNA-antiviral Vaccines: New developments and Approaches – a review. Virus Genes 1998; 17 (3): 219–32.

58. Lai W.C., Bennett M. DNA vaccines. Crit. Rev.Immunol 1998; 18 (5): 449–84.

59. Hooper J., Kamrud K., Elgh F., Custer D., Schmaljohn C. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects Seoul virus infection. Virology. 1999; 255: 269–278.

60. Kamrud K., Hooper J., Elgh F., Schmaljohn C. Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing hantavirus structural genes in hamsters. Virology, 1999; 263: 209–219.

61. Boudreau E., Sellers K., Rusnak J. et al. Phase 1 clinical study on the safety, tolerability and immunogenicity of Hantaan and Puumala DNA vaccines. In: Abstracts of the 8th international conference on HFRS HPS and hantavirus, Athens, 2010. p. 83.

62. Filatov F, Tkachenko E, Schmaljohn C, Hooper J et al. Immune response to aerosol delivery of the cloned hantavirus genes. In: Abstracts of 7th international conference on HFRS, HPS and hantaviruses, Buenos Aires, 2007. p. 187.

63. Boudreau E.F., Josleyn M., Ullman D. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome. Vaccine. 2012; 30: 1951–1958.

64. Zhao C., Zhao Y.S, Wang S. Immunogenicity of a multiepitope DNA vaccine against hantavirus. Hum Vaccines Immunother. 2012; 8 (2): 208–215.

65. Schmaljohn C.S, Spik K.W, Hooper J.W. DNA vaccines for HFRS: laboratory and clinical studies. Virus Res. 2014. 187:91-6.

66. Kwilas S., Kishimori J.M., Josleyn M. et al. A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates. Current Gene Therapy. 2014; 14: 200–210.

67. McCoy J.R., Mendoza J.M., Spik K.W. et al. Schmaljohn C.S., Sardesai N.Y., Broderick K.E. A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin. Hum Vaccin Immunother. 2015; 11 (3): 746–54.

68. Hooper J.W., Moon J.E., Paolino K.M. et al. Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Clin Microbiol Infect. 2014; 20 (5): 110–117.

69. Cichutek K. DNA vaccines: development, standardization and regulation. Intervirology. 2000; 43: 331–8.

70. Haese N., Brocato R.L., Henderson T. et al. Antiviral Biologic Produced in DNA Vaccine/ Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure. PLOS Neglected Trop Dis. 2015; 1: 19.

71. Hooper J.W., Brocato R.L., Kwilas S. A. et al. DNA vaccine–derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome. Sci Transl Med. 2014. 26; 6 (264): 264–70.

72. Kobak L., Raftery M.J., Voigt S. et al. Hantavirus-1 induced pathogenesis in mice with a humanized immune system. J. Gen. Virol. 2015. 96: 1258–63.

73. Hjelle B. Vaccines against hantaviruses. Expert Rev Vaccines. 2002. 1: 373–384.